Motivation: Untargeted metabolomics of host-associated samples has yielded insights into
INTRODUCTION

6
The host-associated microbiome can influence many aspects of human health and disease 3 7 through its metabolic activity. Examples include microbe-host co-metabolism of dietary 3 8 choline/carnitine to TMAO as a driver of heart disease (Wang et al., 2011) , microbial production 3 9
of branched chain amino acids as a contributor to insulin resistance (Pedersen et al., 2016) , and 4 0 microbial production of 12,13-DiHOME as a driver of CD4 + T cell dysfunction associated with 4 1 childhood atopy (Fujimura et al., 2016) . A key way of exploring which compounds might 4 2 mediate relationships between microbial activity and host disease is untargeted metabolomics of which is referred to as a "metabolome". Host-associated metabolomes represent a complex We used AMON to relate the stool microbiome (as assessed with 16S rRNA gene positive individuals (n=37) and HIV-negative controls (n=22). These data represent a subset of 1 1 8 the cohort described in (Armstrong et al., 2018) and are paired with metabolome data as a part of 1 1 9
a study described at ClinicalTrials.gov (Identifier: NCT02258685). The overall goal of our case 1 2 0 study was to use AMON to determine the degree to which annotated compounds in the plasma microbiome are predicted to be capable of producing the observed metabolite). All study participants were recruited from University of Colorado Hospital with an approved Plasma Sample Preparation:
A modified liquid-liquid extraction protocol was used to extract hydrophobic and hydrophilic
compounds from the plasma samples (Yang et al., 2013) . Briefly, 100 µL of plasma spiked with was dried under nitrogen and methyl tert-butyl ether (MTBE) and water were added to extract with water and ice-cold methanol (1:4 water-methanol). The supernatant was removed, dried by
SpeedVac at 45 °C and reconstituted in 100 µL of 5% acetonitrile in water. Both fractions were 1 4 6 stored at -80 °C until LCMS analysis.
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Liquid Chromatography Mass Spectrometry
The hydrophobic fractions were analyzed using reverse phase chromatography on an Agilent
Technologies (Santa Clara, CA) 1290 ultra-high precision liquid chromatography (UHPLC) (HILIC) on a 1290 UHPLC system using a Phenomenex Kinetex HILIC, 2.6um (2.1 x 50mm)
analytical column with an Agilent Zorbax Eclipse Plus C8 5µm (2.1 x12.5mm) guard column.
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The hydrophobic and hydrophilic fractions were run on Agilent Technologies (Santa Clara, CA) fractions were run in positive and negative electrospray ionization (ESI) modes, as previously
described (Heischmann et al., 2016) .
Mass Spectrometry Data Processing
Compound data was extracted using Agilent Technologies (Santa Clara, CA) Mass Hunter Profiler Professional Version 14 (MPP) as described previously (Heischmann et al., 2016) .
Briefly, a naive feature finding algorithm, Find By Molecular Feature, was used in Profinder to of missing values, a theoretical mass and retention time database was generated for compounds 1 6 6 present in samples only. This database was then used to re-search the raw sample data in
Profinder using the Find By Ion algorithm.
An in-house database containing METLIN, Lipid Maps, KEGG, and HMDB spectral data was used to putatively annotate metabolites based on exact mass, isotope ratios and isotopic We used PICRUSt to determine the genome content of the OTUs detected in the fecal human genome to represent human gene content.
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We provided these lists of gut microbiome and human KOs to AMON to produce a list of 1 8 7
compounds generated from the gut microbiome and the human genome. Of the 4,409 unique 1 8 8
KOs that PICRUSt predicted to be present in the gut microbiome, only 1,476 (33.5%) had an exist but for which the exact reaction is unknown, showing gaps in our knowledge (Fig 2A) .
Using information in KEGG, AMON predicted these KOs to produce 1,321 unique compounds 1,809 reactions. putatively annotated with KEGG compound identifiers via a database search; only 471 (6%) of 1 9 7
the 5,971 detected compounds were associated with a reaction in KEGG (Supplemental Table 1 ).
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Of these 471 annotated compounds in the plasma metabolome with associated KEGG reactions, 1 9 9
189 were predicted to be produced by enzymes in either human or stool bacterial genomes. 40 2 0 0 compounds were exclusively produced by bacteria, 58 exclusively by the host, and 91 by either 2 0 1 human or bacterial enzymes (Fig 2B) . The remaining 282 compounds may be 1) from the 2 0 2 environment, 2) produced by microbes in other body sites or 3) host or gut microbial products 2 0 3 from unannotated genes (Supplemental Table 1 ).
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We used AMON to assess enrichment of pathways in the detected human and bacterial and the cysteine and methionine metabolism pathway. The metabolite origin data was visualized 2 1 0 using KEGG mapper for the phenylalanine, tyrosine and tryptophan biosynthesis pathway 2 1 1 ( Figure 3B ). This tool helps to visualize the host-microbe co-metabolism and which genes are allows us to see that Indole is a compound found in our metabolome that could only have been produced by bacterial metabolism via the highlighted enzyme (K01695, tryptophan synthase).
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Also, Tyrosine is a compound found in our metabolome that could have been synthesized by a variety of enzymes found only in bacteria, only in humans, or in both and so further exploration 2 1 7
would be needed to understand origins of this compound. The 51 compounds which were detected and predicted to be produced by the human genome were enriched in pathways that 2 1 9
include bile secretion, steroid hormone biosynthesis and gastric acid secretion. Taken together, these analyses show that AMON can be used to predict the origin of 2 2 3 compounds detected in a complex metabolome, such as stool. Our case study shows the specific versus the host. However, this tool can be used to compare any number of different sources -e.g. from the microbiomes of different body sites or compounds that may come directly from plants
consumed in the diet. Also, the outputs of AMON can be used in conjunction with lists of 2 2 8
metabolites that were determined to significantly differ with disease state or correlate with other host phenotypes to predict origins of metabolites of interest.
Although our example uses PICRUSt to predict compounds of bacterial origin using 16S application to environments with less understood genomes.
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The pathway enrichment of compounds predicted to be unique to the gut microbiome and the predicted to only be from microbes are consistent with known roles for gut bacteria in degrading 2 3 8 various xenobiotics (Maurice et al., 2013; Lu et al., 2015; Das et al., 2016; Saad et al.;  Clayton resistance (Pedersen et al., 2016) .
However, this analysis also highlights limitations in this approach due to issues with annotations are based on peak masses and isotope ratios, which can often represent multiple 2 6 0 compounds and/or in-source fragments; our confidence in the identity of these compounds is 2 6 1 only moderate.
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The situation is even worse for complex microbial communities, where even fewer genes are 2 6 3 of known function. Because of these gaps in our knowledge of metabolite production, efforts to 2 6 4
